R K D Pharmaceutical LLP is a globally focused pharmaceutical export and healthcare sourcing company providing access to high-quality pharmaceutical formulations, APIs, excipients, nutraceuticals, medical devices, surgical consumables, laboratory ins...
- (+91) 9004316713
- ajay.sharma@rkdpharmaceutical.com
- Unit no.414, 4th Floor, Marathon Max, Mulund – Goregaon Link road, Mulund West, , Mumbai, Maharashtra, India. 400080
© 2020 R K D PHARMACEUTICAL LLP. All Rights Reserved
Pharmaceutical Products
Amoxicillin Trihydrate BP 875 mg & Potassium Clavulanate BP 125 mg
Strength & Pharmacopoeial Grade
Amoxicillin Trihydrate BP 875 mg & Potassium Clavulanate BP 125 mg is a fixed-dose antibacterial combination intended for oral tablet formulations. Each stated dose provides amoxicillin equivalent to 875 mg as amoxicillin trihydrate and clavulanic acid equivalent to 125 mg as potassium clavulanate. Pharmaceutical and institutional buyers should verify the finished-product specification, batch certificate of analysis (COA), registration status and applicable supply documentation before procurement.
Composition & Product Characteristics
The formulation combines a penicillin-class antibacterial, amoxicillin, with clavulanic acid supplied as potassium clavulanate, a beta-lactamase inhibitor. Procurement assessment should cover identity, assay, related substances, dissolution, microbial quality, tablet characteristics and packaging integrity against the approved specification. Excipients, storage conditions, pack configuration and market-specific labelling should be confirmed from the manufacturer’s technical dossier and batch documentation.
Amoxicillin Trihydrate BP 500 mg & Potassium Clavulanate BP 125 mg
Strength, Dosage Form & Pack Configuration
Amoxicillin Trihydrate BP 500 mg & Potassium Clavulanate BP 125 mg is a fixed-dose combination presented for institutional procurement. The summary highlights the combination identity, strength pairing and pack format considerations. Procurement teams should confirm blister counts, labeling and any local registration requirements.
Dosage-Form-Specific Handling & Administration Context
Follow product label guidance for administration and storage. Buyers should confirm any shelf-life, reconstitution or cold‑chain needs per the supplied product documentation before placing bulk orders.
Artemether 20 mg and Lumefantrine 120 mg Tablets
Strength, Dosage Form & Pack Configuration
Artemether 20 mg and Lumefantrine 120 mg Tablets is listed as a fixed-dose combination intended for antimalarial therapy procurement teams. The SKU identifies the active strengths used in combination therapy. Procurement teams use this SKU when standard combination dosing is required for formulary stocking. Batch-level documentation and shipment packaging are organized for institutional orders to support repeat supply cycles.
Dosage-Form-Specific Handling & Administration Context
Packaging is configured for institutional dispensing and hospital pharmacy stock. Handling and storage follow standard ambient pharmaceutical storage practice; specific reconstitution or administration instructions are determined by the finished product label. Procurement enquiries should specify required pack counts and delivery cadence to align supply planning.
Artemether 40 mg and Lumefantrine 240 mg Tablets
Assay Purity & Pharmacopoeial Grade
Artemether 40 mg and Lumefantrine 240 mg Tablets identifies Artemether 40mg with Lumefantrine 240mg as the stated active pair. The summary describes the combination identity and procurement relevance for public-health and clinic procurement teams. Verification of assay, batch traceability and composition is recommended on quotation.
Composition & Physicochemical Properties
The entry lists both active ingredients and their strengths. Buyers should confirm formulation form and intended dosage presentation before ordering; packaging and labelling follow institutional requirements.
Artemether 80 mg and Lumefantrine 480 mg Tablets
Assay Purity & Pharmacopoeial Grade
Artemether 80 mg and Lumefantrine 480 mg Tablets is listed as a fixed-dose pairing for procurement. The summary concentrates on the combination identity and batch documentation expectations for program and institutional buyers. Buyers should confirm required assay parameters prior to ordering.
Composition & Physicochemical Properties
The SKU specifies both active strengths. Procurement teams should confirm intended dosage presentation and packaging format to ensure compatibility with dispensing workflows and program distribution plans.
Esomeprazole Tablets 20 mg
Strength, Dosage Form & Pack Configuration
Esomeprazole Tablets 20 mg is identified by strength for procurement purposes. The SKU supports hospital and pharmacy formularies requiring a 20 mg dose. Buyers should specify pack counts and preferred packaging type when requesting quotations so supply can be aligned to dispensing and inventory workflows.
Dosage-Form-Specific Handling & Administration Context
Handling and storage follow label guidance for the finished dosage form. Confirm secondary packaging and labeling requirements at RFQ stage to meet local regulatory and dispensing practices.
Ciprofloxacin Tablets USP 500 mg
Strength, Dosage Form & Pack Configuration
Ciprofloxacin Tablets USP 500 mg is a finished oral dosage product listed by strength and form for procurement teams. The summary underlines pack configuration, labeling and institutional use. Buyers should confirm blister/bottle choices and regulatory labeling needs prior to ordering.
Dosage-Form-Specific Handling & Administration Context
Follow label instructions for administration and storage. Procurement should confirm shelf-life and handling requirements with the supplier to ensure compatibility with institutional inventory management.
Azithromycin Tablets BP 250 mg
Strength, Dosage Form & Pack Configuration
Azithromycin Tablets BP 250 mg are provided as a finished dosage form and listed for procurement. The summary emphasizes pack configuration, strength and suitability for institutional dispensing. Buyers should confirm labeled pack counts and storage recommendations when arranging bulk supply.
Dosage-Form-Specific Handling & Administration Context
Storage and handling follow product label guidance; confirm shelf-life details and any required documentation prior to ordering in bulk.
Azithromycin Tablets BP 500 mg
Strength, Dosage Form & Pack Configuration
Azithromycin Tablets BP 500 mg are listed as a finished dosage formulation with the BP reference in the title. The summary highlights strength, pack choices and institutional suitability. Procurement should confirm blister vs bottle packing and labelling needs prior to ordering.
Dosage-Form-Specific Handling & Administration Context
Follow label guidance for administration and storage. Buyers should request shelf-life and batch documentation details during quote stage to confirm compliance with institutional requirements.
Albendazole Tablets USP 400 mg
Strength, Dosage Form & Pack Configuration
Albendazole Tablets USP 400 mg is presented as a finished dosage formulation with a stated strength for procurement teams. The listing focuses on pack configuration, strength confirmation and suitability for institutional stocking. Buyers should confirm blister or bottle pack configurations and labeling requirements prior to order.
Dosage-Form-Specific Handling & Administration Context
Handling aligns with standard oral solid dosage procedures. Storage recommendations and patient administration notes should be followed as per the product label. Procurement should confirm expiry and shelf-life details when arranging bulk supply.
Atorvastatin Tablets 10 mg
Assay Purity & Pharmacopoeial Grade
Atorvastatin Tablets 10 mg identifies the active strength used in formulation and institutional stock lists. Content focuses on active identity and procurement suitability for manufacturers and hospital formulary procurement teams. Key buyer checks include assay confirmation and impurity limits in the batch COA.
Composition & Physicochemical Properties
The SKU represents the active ingredient at the stated strength. Buyers should confirm solubility, particle-size distribution, and any specified residual solvent limits to ensure compatibility with downstream excipient and processing steps.
Atorvastatin Tablets 20 mg
Assay Purity & Pharmacopoeial Grade
Atorvastatin Tablets 20 mg denotes the core active ingredient and strength used in lipid‑lowering formulations. The listing focuses on the active compound identity, assay expectations and procurement suitability for formulation and institutional buyers. Buyers evaluating this SKU will prioritise certificate-of-analysis (COA) traceability and batch assay data when assessing lots for downstream formulation.
Composition & Physicochemical Properties
The product is presented as the active pharmaceutical substance at the stated strength. Technical procurement should confirm assay, impurity profile and solubility compatibility with selected excipients. Typical evaluation covers assay %, residual solvents and packaging formats suitable for formulation and QC workflows.
Amlodipine Besylate Tablets USP 5 mg
Strength, Dosage Form & Pack Configuration
Amlodipine Besylate Tablets USP 5 mg specifies a commonly procured tablet strength for outpatient and inpatient cardiovascular formularies. The entry indicates USP reference for quality evaluation and supports procurement planning for routine dispensing. Buyers should confirm preferred pack-counts and blister versus bottle formats when requesting quotations to align supply and labeling requirements.
Dosage-Form-Specific Handling & Administration Context
Tablets are compatible with standard ambient storage and typical hospital pharmacy dispensing workflows. Confirm secondary packaging and any serialization or labeling requirements at RFQ stage to ensure compliance with local distribution practices.
Amlodipine Besylate Tablets USP 10 mg
Strength, Dosage Form & Pack Configuration
Amlodipine Besylate Tablets USP 10 mg identifies the active salt and pharmacopoeial reference used for procurement and quality assessment. This SKU indicates a finished-dosage tablet at the specified 10 mg strength. Institutional buyers commonly source this strength for chronic-care formularies and outpatient dispensing. Specify pack format and monthly requirement when requesting procurement proposals to align supply planning and labeling.
Dosage-Form-Specific Handling & Administration Context
Tablets are supplied in blister or bottle configurations according to buyer preference and regulatory labeling needs. Storage follows ambient pharmaceutical storage guidance per the product label. Procurement teams should confirm pack-count and secondary packaging for hospital stocking and ward distribution.
Metformin Tablets 500mg
Strength, Dosage Form & Pack Configuration
Metformin Tablets 500mg denotes a widely stocked oral solid dosage strength for diabetes management formularies. The SKU is used by hospital pharmacies, outpatient clinics, and chain pharmacies for routine dispensing. Buyers should specify preferred pack-counts and blister or bottle format when submitting procurement requests to ensure packaging and labeling meet local distribution norms.
Dosage-Form-Specific Handling & Administration Context
Tablets are stored under standard ambient conditions per label guidance. Procurement teams should confirm secondary packaging, serialization, and palletization needs when issuing RFQs for large-volume orders.
Paracetamol Tablets 500mg
Active Strength & Dosage Form
Paracetamol Tablets 500mg are oral solid-dose products containing 500 mg of paracetamol in each tablet. Paracetamol is an analgesic and antipyretic active ingredient used for the symptomatic relief of pain and fever. Pharmaceutical distributors and institutional buyers should verify the dosage-form specification, applicable pharmacopoeial standard, batch certificate of analysis (COA) and destination-market authorization before procurement.
Composition & Product Characteristics
Each tablet contains 500 mg of paracetamol together with formulation-specific excipients required for manufacturing, stability and tablet performance. Technical evaluation should cover identification, assay, related substances, dissolution, disintegration, uniformity of dosage units, microbial quality and packaging integrity against the approved finished-product specification. Tablet appearance, excipient composition, pack configuration and storage requirements must be confirmed from the manufacturer’s product dossier and batch documentation.
Aceclofenac 100mg & Paracetamol 500mg Tablets
Active Strength & Dosage Form
Aceclofenac 100mg & Paracetamol 500mg Tablets are fixed-dose oral tablets containing 100 mg of aceclofenac and 500 mg of paracetamol per unit. The combination brings together aceclofenac, a non-steroidal anti-inflammatory drug, and paracetamol, an analgesic and antipyretic ingredient. Pharmaceutical distributors and institutional procurement teams should verify the dosage-form specification, batch certificate of analysis (COA), prescription classification and destination-market authorization before purchasing.
Composition & Product Characteristics
Each tablet contains aceclofenac 100 mg and paracetamol 500 mg together with formulation-specific excipients used to support manufacturing and tablet performance. Finished-product assessment should cover identification and assay of both active ingredients, related substances, dissolution, disintegration, uniformity of dosage units, microbial quality and packaging integrity. Tablet coating, appearance, excipient composition, storage conditions and pack configuration should be confirmed through the manufacturer’s approved specification and technical documentation.
Cetirizine Hydrochloride Tablets BP 10 mg
Active Strength & Pharmacopoeial Grade
Cetirizine Hydrochloride Tablets BP 10 mg are oral antihistamine tablets containing 10 mg of cetirizine hydrochloride per unit. The BP designation indicates that the product is intended to comply with the applicable British Pharmacopoeia requirements. Pharmaceutical distributors and institutional buyers should verify the finished-product specification, batch certificate of analysis (COA), market authorization and supporting pharmacopoeial documentation before procurement.
Composition & Product Characteristics
Each tablet contains 10 mg of cetirizine hydrochloride together with formulation-specific excipients used to support manufacturing, stability and tablet performance. Technical assessment should cover identification, assay, related substances, dissolution, disintegration, uniformity of dosage units, microbial quality and packaging integrity against the approved specification. Tablet coating, appearance, scoring, excipient composition and storage requirements should be confirmed from the manufacturer’s technical dossier and batch documentation.
Levocetirizine Dihydrochloride Tablets USP 10 mg
Active Strength & Pharmacopoeial Grade
Levocetirizine Dihydrochloride Tablets USP 10 mg are presented as oral antihistamine tablets containing the stated strength of levocetirizine dihydrochloride. The USP designation indicates intended alignment with applicable United States Pharmacopeia requirements. Because commonly authorized levocetirizine tablet products are documented at 5 mg, buyers should specifically verify the stated 10 mg strength through the manufacturing license, finished-product specification, batch certificate of analysis (COA) and destination-market authorization.
Composition & Product Characteristics
The stated formulation contains levocetirizine dihydrochloride together with product-specific excipients required for tablet manufacture, stability and performance. Technical procurement should assess active-ingredient identity and assay, related substances, dissolution, disintegration, uniformity of dosage units, microbial quality and packaging integrity. Tablet appearance, coating, scoring, excipient composition, storage conditions and pack configuration should be confirmed from the manufacturer’s approved dossier and batch documentation.
Cefixime for Oral Suspension USP 100mg (60ml)
Strength, Dosage Form & Pack Configuration
Cefixime for Oral Suspension USP 100mg (60ml) is listed for pharmacy and clinical procurement. The summary emphasises the provided strength and pack size. Buyers should confirm labeling, dispensing instructions and any required package inserts.
Dosage-Form-Specific Handling & Administration Context
Follow label instructions for storage and administration. Confirm any post‑reconstitution shelf life or handling recommendations from the product documentation prior to clinical use.
Cefuroxime Axetil for Oral Suspension USP 125 mg (100ml)
Strength, Dosage Form & Pack Configuration
Cefuroxime Axetil for Oral Suspension USP 125 mg (100ml) is presented for pharmacy procurement. The block highlights the strength and container pairing as provided in the product title. Buyers should confirm pack labelling and dispensing instructions where required.
Dosage-Form-Specific Handling & Administration Context
Oral suspension handling and storage should follow the product label. Reconstitution or post‑opening stability instructions must be confirmed from the supplied product documentation prior to dispensing in clinical settings.
Cefpodoxime Proxetil for oral suspension 50 mg (100ml)
Strength, Dosage Form & Pack Configuration
Cefpodoxime Proxetil for oral suspension 50 mg (100ml) is offered for pharmacy procurement. The summary highlights the product's strength and container pairing. Buyers should confirm dispensing labels and pack configurations before purchase.
Dosage-Form-Specific Handling & Administration Context
Storage and administration follow the product label; confirm any post‑reopening stability or reconstitution guidance from supplied documentation prior to clinical use.
Ceftriaxone 250 mg Injection
Active Strength & Injectable Presentation
Ceftriaxone 250 mg Injection is generally presented as a sterile powder containing ceftriaxone sodium equivalent to 250 mg of ceftriaxone in a single-dose vial. The powder requires reconstitution with an approved diluent before administration by a qualified healthcare professional. Hospital and institutional buyers should verify the pharmacopoeial standard, route of administration, batch certificate of analysis (COA), sterility documentation and destination-market authorization before procurement.
Composition & Physicochemical Properties
The vial contains ceftriaxone in the form of ceftriaxone sodium, typically supplied as a white to yellowish crystalline powder for solution for injection. Technical evaluation should cover identification, potency, related substances, water content, particulate matter, sterility, bacterial endotoxins and container-closure integrity against the approved specification. Compatible diluents, reconstitution instructions, solution stability and administration conditions must be confirmed from the manufacturer’s approved product information.
Ceftriaxone 500 mg Injection
Assay Purity & Pharmacopoeial Grade
Ceftriaxone 500 mg Injection is provided as an active-strength listing without an explicit dosage form. The summary focuses on assay verification, impurity profile and procurement suitability for formulation or institutional use. Buyers should request COA to verify batch parameters before acceptance.
Composition & Physicochemical Properties
The SKU identifies the active at the stated strength. Procurement assessments should confirm intended presentation and any sterility or packaging needs with the supplier to ensure compatibility with downstream processes.
Ceftriaxone 1000 mg Injection
Assay Purity & Pharmacopoeial Grade
Ceftriaxone 1000 mg Injection is listed as the active strength without an explicit dosage form in the product title. The summary treats this entry as the active-strength SKU and focuses on procurement checks such as assay, impurity profile and batch documentation. Buyers should request COA to verify assay and related QC parameters.
Composition & Physicochemical Properties
The entry denotes the active compound at the given strength. Procurement evaluation should consider solubility, handling and any sterility requirements if the intended use is injectable; confirm form and presentation with the supplier.
Ceftriaxone & Sulbactam for Injection 1.5 g
Strength, Dosage Form & Pack Configuration
Ceftriaxone & Sulbactam for Injection 1.5 g denotes the combination strength intended for injectable preparation. The summary concentrates on the combination identity and procurement considerations for clinical inventories. Buyers should confirm vial count and presentation as part of purchase planning.
Dosage-Form-Specific Handling & Administration Context
Injectable handling and administration must follow product labeling and local clinical protocols. Confirm diluent compatibility, reconstitution instructions and cold‑chain requirements from supplied product documentation when applicable.
Bulk Pharmaceutical Products targets distributors, hospitals and pharmacies evaluating finished-product formats, packaging and supply continuity for repeat procurement.
Product formats and packaging
Compare tablets, oral liquids and sterile finished formats by packaging options that suit storage and dispensing workflows.
Selection and use-case fit
Match product format to clinical or retail use, and consider shelf-life and handling requirements when selecting pack sizes.
Supply planning and lot control
Plan reorder cadence and lot-trace processes to support recalls and inventory rotation; align pack formats to dispensing velocity.
Commercial evaluation points
Request tiered pricing and contract terms to compare landed costs across volumes and repeat-order scenarios.
Q: What MOQ options are available for finished pharmaceutical products?
A: MOQ varies by product and packaging; suppliers can provide tiered MOQ and bulk pack alternatives during quoting.
Q: How does pricing typically scale for bulk finished pharmaceuticals?
A: Pricing usually moves in volume bands; request volume-break pricing to model procurement budgets.
Q: Which traceability documents should be requested for finished drugs?
A: Ask for batch traceability and any available quality records relevant to the finished product class.
Q: What packaging standards support safe international transport of drugs?
A: Confirm protective inner packaging and palletization standards with suppliers to meet transport handling requirements.
